Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 38 of 38 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
KIT D816V	systemic mastocytosis	resistant		Imatinib	FDA contraindicated	Actionable	Gleevec (imatinib) is not indicated for patients with aggressive systemic mastocytosis harboring KIT D816V (FDA.gov).	detail...
KIT D816V	systemic mastocytosis	not applicable		N/A	Guideline	Diagnostic	KIT D816V aids in the diagnosis of systemic mastocytosis (NCCN.org).	detail...
KIT D816V	systemic mastocytosis	not applicable		N/A	Guideline	Prognostic	KIT D816V is associated with an adverse prognosis in patients with systemic mastocytosis (NCCN.org).	detail...
KIT D816V	systemic mastocytosis	sensitive	Avapritinib	Avapritinib	Phase II	Actionable	In a Phase II trial (PATHFINDER), Ayvakit (avapritinib) treatment resulted in an objective response rate of 75% (24/32) in evaluable patients (pts) with advanced systemic mastocytosis, at 10.4 mo median follow-up, 84% (52/62) of pts remained on study, with median overall survival (OS) not reached, median time to response of 2 mo, an estimated 12 mo OS of 87%, and KIT D816V allele reduction in 53% of pts (33/62) (AACR Annual Meeting, Apr 2021, Abstract CT023; NCT03580655).	detail...
KIT D816V	mast cell neoplasm	predicted - sensitive	Avapritinib	Avapritinib	Phase I	Actionable	In a Phase I trial, patients with either aggressive systemic mastocytosis, mast cell leukemia, or systemic mastocytosis with an associated hematologic neoplasm harboring KIT D816V demonstrated a reduction in mast cell burden and a decrease in KIT D816V allelic fraction when treated with Ayvakit (avapritinib) (ASH Annual Meeting, Dec 2017, Plenary 2).	detail...
KIT D816V	acute myeloid leukemia	sensitive		Cytarabine + Dasatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with acute myeloid leukemia harboring KIT D816V achieved long-term remission and loss of KIT D816V following treatment with the combination of Sprycel (dasatinib) and Cytosar-U (cytarabine) (PMID: 18986703).	18986703
KIT D816V	hematologic cancer	resistant		Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematopoietic cells expressing KIT D816V demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 17229632).	17229632
KIT D816V	Advanced Solid Tumor	predicted - sensitive		BPR1J373	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were sensitive to BPR1J373, demonstrating inhibition of Kit phosphorylation (PMID: 27512117).	27512117
KIT D816V	hematologic cancer	sensitive		FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101, as compared to Quizartinib, inhibited cell proliferation of transformed 32Dcl3 murine myeloid cells expressing human Kit D816V (PMID: 29187377).	29187377
KIT D816V	Advanced Solid Tumor	resistant		Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were resistant to treatment with Sutent (sunitinib) in culture (PMID: 24205792).	24205792
KIT D816V	Advanced Solid Tumor	resistant		Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were resistant to treatment with Flumatinib in culture (PMID: 24205792).	24205792
KIT D816V	hematologic cancer	sensitive		Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT D816V	hematologic cancer	sensitive		Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT D816V	hematologic cancer	sensitive	Avapritinib	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ayvakit (avapritinib) inhibited Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT D816V	hematologic cancer	resistant		Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) did not inhibit Kit phosphorylation or growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT D816V	hematologic cancer	resistant		Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vanflyta (quizartinib) did not inhibit Kit phosphorylation or growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT D816V	hematologic cancer	predicted - sensitive		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) demonstrated moderate inhibition of Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT D816V	acute myeloid leukemia	sensitive		Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT D816V	acute myeloid leukemia	sensitive		Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT D816V	acute myeloid leukemia	sensitive	Avapritinib	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ayvakit (avapritinib) inhibited Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT D816V	acute myeloid leukemia	resistant		Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) did not inhibit Kit phosphorylation or growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT D816V	acute myeloid leukemia	resistant		Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vanflyta (quizartinib) did not inhibit Kit phosphorylation or growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT D816V	acute myeloid leukemia	predicted - sensitive		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) demonstrated moderate inhibition of Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT D816V	Advanced Solid Tumor	sensitive		Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were sensitive to treatment with Rydapt (midostaurin) in culture, demonstrating decreased cell proliferation (PMID: 31270078).	31270078
KIT D816V	Advanced Solid Tumor	sensitive	Avapritinib	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were sensitive to treatment with Ayvakit (avapritinib) in culture, demonstrating decreased cell proliferation (PMID: 31270078).	31270078
KIT D816V	Advanced Solid Tumor	sensitive		Ripretinib	Preclinical - Cell culture	Actionable	In a preclinical study, Qinlock (ripretinib) inhibited proliferation of transformed cells expressing KIT D816V in culture (PMID: 31085175).	31085175
KIT D816V	Advanced Solid Tumor	resistant		Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were resistant to Stivarga (regorafenib) in culture (PMID: 31085175).	31085175
KIT D816V	hematologic cancer	sensitive	Dasatinib	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were sensitive to treatment with Sprycel (dasatinib) in culture, demonstrating reduced cell survival (PMID: 31182436).	31182436
KIT D816V	Advanced Solid Tumor	resistant		Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) treatment did not inhibit proliferation of transformed cells expressing KIT D816V in culture (PMID: 30523507).	30523507
KIT D816V	Advanced Solid Tumor	sensitive		PLX9486	Preclinical - Cell culture	Actionable	In a preclinical study, PLX9486 treatment inhibited proliferation of Gleevec (imatinib)-resistant transformed cells expressing KIT D816V in culture (PMID: 30523507).	30523507
KIT D816V	Advanced Solid Tumor	resistant		Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were resistant to Gleevec (imatinib) treatment in culture (PMID: 35194937).	35194937
KIT D816V	Advanced Solid Tumor	resistant		Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) did not inhibit growth of transformed cells expressing KIT D816V in culture (PMID: 22301675).	22301675
KIT D816V	Advanced Solid Tumor	resistant		Sunitinib	Preclinical	Actionable	In a preclinical study, KIT D816V mutations demonstrated resistance to Sutent (sunitinib) in a biochemical assay (PMID: 19164557).	19164557
KIT D816V	Advanced Solid Tumor	decreased response		Nilotinib	Preclinical	Actionable	In a preclinical study, Tasigna (nilotinib) decreased viability of cells expressing KIT D816V in culture, but did not inhibit KIT phosphorylation or growth of KIT D816V-expressing tumors in mouse models (PMID: 20442311).	20442311
KIT D816V	Advanced Solid Tumor	resistant		Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Gleevec (imatinib mesylate) in culture (PMID: 15790786).	15790786
KIT D816V	hematologic cancer	resistant		Imatinib	Preclinical	Actionable	In a preclinical study, a mouse myeloid cell line expressing KIT D816V demonstrated resistance to Gleevec (imatinib) in culture (PMID: 12481435).	12481435
KIT D816V	Advanced Solid Tumor	resistant		Cabozantinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Cometriq (cabozantinib) in culture (PMID: 24205792).	24205792
KIT D816V	Advanced Solid Tumor	resistant		Quizartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Quizartinib in culture (PMID: 23497317).	23497317

Showing 1 to 38 of 38 entries

Filter rows:

Profile Name	KIT D816V
Gene Variant Detail	KIT D816V (gain of function)
Relevant Treatment Approaches	Avapritinib Dasatinib

Molecular Profile Detail

Contact

Filtering

Sorting